REQUEST A DEMO
Total
USD $0.00
Search more companies

Scigen Pte. Ltd. (Singapore)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Scigen Pte. Ltd. Profile Updated: April 07, 2019
Buy our report for this company USD 19.99 Most recent financial data: 2017 Available in: English Download a sample report

Scigen Limited is engaged in developing, manufacturing, and marketing recombinant human health care biotechnology derived products including human growth hormone, human insulin and human GCSF. The company focuses in the areas of endocrinology, gastroenterology and immunology. Scigen Limited is headquartered in Singapore with in Australia, China, India, Korea, Philippines and Vietnam, partners and distributors in all other countries. The company operates as a subsidiary of Bioton S.A.

Legal Address
Suite 1,13b Narabang Way,Belrose
Sydney; New South Wales‎; Postal Code: 2085

Contact Details: Purchase the Scigen Pte. Ltd. report to view the information.

Basic Information
Outstanding Shares:
Purchase the Scigen Pte. Ltd. report to view the information.
Financial Auditors:
Purchase the Scigen Pte. Ltd. report to view the information.
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Chief Financial Officer
Purchase this report to view the information.
Board Member
Purchase this report to view the information.
Board Member
Purchase this report to view the information.
Board Member
Ownership Details
Purchase this report to view the information.
95.57%
Company Performance
Financial values in the chart are available after Scigen Pte. Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency USD. Absolute financial data is included in the purchased report.
Net sales revenue
38.63%
Total operating revenue
38.5%
Operating profit (EBIT)
4.01%
EBITDA
3.94%
Net Profit (Loss) for the Period
-14.25%
Total assets
12.22%
Total equity
4.45%
Operating Profit Margin (ROS)
-3.48%
Net Profit Margin
-2.7%
Return on Equity (ROE)
0.38%
Debt to Equity Ratio
-3.63%
Quick Ratio
0.72%
Cash Ratio
0.49%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?